Navigation Links
NicOx Initiates Two Large ABPM Studies for Naproxcinod in Hypertensive Patients with Osteoarthritis
Date:3/3/2008

d pressure increase. Both treated hypertensive patients and individuals with normal blood pressure appear to be affected and the dose and duration of administration also seems to be important, with hypertension occurring more frequently with chronic treatment.

NOTE 2: Ambulatory Blood Pressure Measurement (ABPM) involves using a portable device to independently measure and record blood pressure at frequent intervals over a 24-hour period with minimal disruption of a subject's daily activity. In these new studies, blood pressure measurements will be taken at 20-minute intervals between 6:00 am and 10:00 pm and every hour from 10:01 pm to 5:59 am.

NicOx (Bloomberg: COX:FP, Reuters: NCOX.PA) is a product-driven biopharmaceutical company dedicated to the development and future commercialization of investigational drugs for unmet medical needs. NicOx is applying its proprietary nitric oxide-donating technology to develop an internal portfolio of New Chemical Entities (NCEs) in the therapeutic areas of inflammatory and cardio-metabolic disease.

Resources are focused on the development of naproxcinod, a proprietary NCE and the first compound in the COX-Inhibiting Nitric Oxide-Donating (CINOD) class of anti-inflammatory agents, which is in phase 3 clinical studies for the treatment of the signs and symptoms of osteoarthritis, with final phase 3 results anticipated in 2008.

Beyond naproxcinod, NicOx has a pipeline containing multiple nitric oxide- donating NCEs, which are in development internally and with partners, including Pfizer Inc and Merck & Co., Inc., for the treatment of prevalent and underserved diseases, such as atherosclerosis, hypertension, glaucoma and Chronic Obstructive Pulmonary Disease (COPD).

NicOx S.A. is headquartered in France and is listed on the Euronext Paris Stock Exchange (Compartment B: Mid Caps).

This press release contains certain forward-looking statements. Although the Company believes its expectations
'/>"/>

SOURCE NicOx S.A.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. NicOx to Present at Financial Conferences in New York on November 27, 28 and 29
2. NicOx Opens U.S. Headquarters in New Jersey
3. Circassia Initiates Phase II Clinical Study With Novel Anti-Allergy Technology
4. Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
5. Accelerated Community Oncology Research Network, Inc. (ACORN), Initiates a Phase 2b Metastatic Breast Cancer Trial in Cooperation With Bayer and Onyx
6. Rib-X Pharmaceuticals Initiates Two Phase 2 Studies for Novel Antibiotic Compound RX-1741
7. Memory Pharmaceuticals Initiates Phase 2a Trial of MEM 3454 in Cognitive Impairment Associated with Schizophrenia
8. Conatus Pharmaceuticals Initiates a Phase 2 Clinical Trial for the Treatment of Hepatitis
9. Human Genome Sciences Initiates Second Randomized Phase 2 Trial of HGS-ETR1 in Combination With Chemotherapy
10. GeneNews initiates patient sample accrual for validation studies of colon cancer blood test
11. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... ... July 30, 2015 , ... Leading regenerative veterinary medicine company, ... canine osteoarthritis stem cell product, currently under development for FDA approval. The product ... marketed in the US by Aratana. This product, termed AT-016, is an allogeneic ...
(Date:7/30/2015)... 30, 2015 Ascendis Pharma A/S (Nasdaq: ... its innovative TransCon technology to address significant unmet ... a six-month Phase 2 study to evaluate the ... in 53 treatment-naïve, pre-pubertal children with growth hormone ... pleased with the top-line results from our Phase ...
(Date:7/30/2015)... ... July 30, 2015 , ... GEA's Pony™ NS2006L ... operation up to 1500 bar. The sanitary design gauge of the NS2006L is ... , The Pony™ NS2006L homogenizer is an ideal solution for the processing of ...
(Date:7/29/2015)... US-Australian drug discovery company, Novogen Limited (ASX: ... committed to progressing its ground-breaking technology platforms to Phase ... ensure the Company delivers the best value for shareholders. ... , said the Company currently had an extensive program ... programs and academic partnerships and initiatives, and he was ...
Breaking Biology Technology:VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 4Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 5Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 6Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 7Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 8Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 9Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 10
... Reagents to ... Advance Cancer Research, NEWARK, ... ) -- a leader in providing advanced antibody,products and services ... by Science Applications International Corporation - Frederick,(SAIC-F), to develop monoclonal ...
... 7 at 1:45 PM, DALLAS, April 3, 2008 ... digital health research at ATA 2008 at the,Washington State ... Harry will highlight findings from Private Insurance and ... insurance industry featuring,interviews with twenty senior executives from the ...
... Ratcliff, the,award-winning architecture, planning and interiors firm, master ... tower,accompanied by a 767-stall parking garage and 20,000-square-foot ... Walnut Creek Campus. The Thomas J.,and Muriel T. ... will add,230 private and six semi-private rooms, increasing ...
Cached Biology Technology:Strategic Diagnostics Inc. Selected as Key Supplier to SAIC-F and the National Cancer Institute for the Development of a Comprehensive Portfolio of Antibodies for Use in Cancer Research 2Strategic Diagnostics Inc. Selected as Key Supplier to SAIC-F and the National Cancer Institute for the Development of a Comprehensive Portfolio of Antibodies for Use in Cancer Research 3Parks Associates' Digital Health Analyst to Present Latest Research and Forecasts at ATA Show 2Ratcliff Designs Hospital of the Future for John Muir Medical Center - Walnut Creek Campus 2Ratcliff Designs Hospital of the Future for John Muir Medical Center - Walnut Creek Campus 3
(Date:7/13/2015)... , Jul. 13, 2015 NXT-ID, Inc. ... a biometric authentication company focused on the growing ... filed provisional patent 62/188684 for BEHAVIORAL-DIRECTED ... another new convenient and secure method to make ... innovative payment methods, introduced with its groundbreaking voice-direct ...
(Date:7/8/2015)... 2015 Summary Pancreatic cancer is the ... fatal, with a mortality rate of 10.9 deaths per ... cancer patients has highlighted a significant need for new ... met by the current market. A highly active ... varying molecule types and mechanisms of action, which provides ...
(Date:7/7/2015)... VIEW, Calif. , July 7, 2015 /PRNewswire/ ... biometrics market, Frost & Sullivan recognizes Credence ID, ... Sullivan Entrepreneurial Company of the Year Award. ... suite to aid in its mission of offering ... under-recognized populations globally. As Credence ID was formed ...
Breaking Biology News(10 mins):NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5
... 2009 issue of the Journal of General Physiology ... University of British Columbia, Vancouver) and colleagues that explores ... using in vivo nonsense suppression technology. The study will ... According to Riccardo Olcese (UCLA) in a commentary accompanying ...
... DURHAM, N.H. Two University of New Hampshire ... (NSF) Faculty Early Career Development (CAREER) grants. Vaughn ... biomedical sciences received $1 million to better understand ... students in data collection. Christopher White of the ...
... Mountain goats are no exception to the general ... healthier offspring. But University of Alberta researcher David Coltman ... mountain goats think twice about their romantic partners. ... taking the eligible females for themselves. The larger males ...
Cached Biology News:2 UNH faculty receive $1.4M in CAREER grants from NSF 2
Standard 2" or 3" Plastic can be ordered with 81 or 100 cell dividers. Mini 2" Plastics Boxes come standard with 25 cell dividers. Plastic boxes can also be ordered with corresponding freezer racks...
Ultra Pure Grade. Used in conjunction with IPTG to identify bacterial colonies that contain recombinant plasmids by blue/white selection. X-Gal forms an intense blue precipitate in the presence of be...
Request Info...
4-Hydroxy-3-nitrophenylacetyl hapten is conjugated to KLH (Keyhole Limpet Hemocyanin) lysine through amide bonds....
Biology Products: